TEVA Teva Pharmaceutical Industries Limited American Depositary Shares

10.39
-0.06  -1%
Previous Close 10.45
Open 10.38
Price To Book 0.82
Market Cap 11,346,809,084
Shares 1,092,089,421
Volume 12,048,869
Short Ratio 4.52
Av. Daily Volume 18,243,401
Stock charts supplied by TradingView

NewsSee all news

  1. Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance at 8 a.m. ET on February 12, 2020

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2019 financial results, as well as on its financial guidance for 2020, on

  2. Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco,

  3. NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology

  4. Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") to purchase for cash for a combined

  5. Zimmerman BioPharmaceuticals Set To Monetize From The $42.9 Billion Insulin Market

    November 20, 2019 – 665 Energy, Inc. (OTC:SSOF) acquired Zimmerman BioPharmaceuticals (ZBP), the owner of a patent-protected process that will deliver insulin to consumers at 80% of current prices. The global

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial met co-primary endpoints - August 16, 2018. Low dose arms only.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
FDA Approval announced November 28, 2018.
TRUXIMA
Rituxan (rituximab) biosimilar
FDA approval announced December 14, 2018.
HERZUMA
Herceptin biosimilar
Approved January 15, 2018.
Trisenox
Acute Promyelocytic Leukemia
FDA Approval announced September 14, 2018.
Fremanezumab
Migraine
Phase 3 trial commenced 1Q 2018.
AUSTEDO SD-809
Tourette Syndrome
Phase 2 trial initiated 2H 2017.
Fremanezumab
Post-Traumatic Headache
Phase 3 ongoing
Fasinumab
Lower back pain
Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018.
Fremanezumab
Cluster headache

Latest News

  1. Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance at 8 a.m. ET on February 12, 2020

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2019 financial results, as well as on its financial guidance for 2020, on

  2. Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco,

  3. NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology

  4. Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") to purchase for cash for a combined

  5. Zimmerman BioPharmaceuticals Set To Monetize From The $42.9 Billion Insulin Market

    November 20, 2019 – 665 Energy, Inc. (OTC:SSOF) acquired Zimmerman BioPharmaceuticals (ZBP), the owner of a patent-protected process that will deliver insulin to consumers at 80% of current prices. The global

  6. Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes

    Proceeds to Repay Existing Debt Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that it successfully upsized and priced approximately $2.1 billion (equivalent) of its senior notes

  7. Teva Announces $1.5 Billion Debt Tender Offers

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has commenced tender offers (the "Offers") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid

  8. Teva Announces Launch of $1,500,000,000 Offering of Senior Notes

    Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today the following private offering of senior notes: Teva Pharmaceutical Finance Netherlands II B.V. ("Teva Finance II") intends to

  9. Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States

    TRUXIMA Available Week of November 11 Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX KRX:068270) and Celltrion Healthcare, Co., Ltd.

  10. Teva Announces Appointment of New Chief Financial Officer

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eli Kalif as Executive Vice President and Chief Financial Officer. Mr. Kalif will begin his employment on December 22, 2019.

  11. Teva Reports Third Quarter 2019 Financial Results

    Revenues of $4.3 billion GAAP diluted loss per share of $0.29 Non-GAAP diluted EPS of $0.58 Free cash flow of $551 million Spend base reduction of $2.9 billion since initiation of the restructuring plan in

  12. Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019 (Updated Dial-in Information)

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a

  13. Teva Canada Announces the Launch of a Bioequivalent Generic Version of [Pr]Gilenya®, [Pr]Teva-Fingolimod Capsules for the treatment of Relapsing-Remitting Multiple Sclerosis (MS)

     - Currently Available in Canada - TORONTO, Oct. 31, 2019 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of PrTeva-Fingolimod 0.5 mg capsules, a Health Canada

  14. Teva Settles Track 1 Opioid Cases and Reaches Agreement on Framework to Settle Remaining Litigation

    Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties' claims and removes Teva from the Track

  15. Teva to Host Conference Call to Discuss Third Quarter 2019 Financial Results at 8 a.m. ET on November 7, 2019

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a

  16. Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at Psych Congress 2019

    Three new presentations evaluate AUSTEDO tablets for the treatment of tardive dyskinesia in adults Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data

  17. Teva Announces Leadership Change in its Global Operations Group

    Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced today the retirement of Dr. Carlo de Notaristefani, and the appointment of Eric Drapé as Executive Vice President, Global Operations. Dr. de Notaristefani

  18. INTERCURE: CANNDOC signs strategic distribution agreement with S.L.E. of TEVA Pharmaceuticals

    HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (TASE: INCR), announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva

  19. Teva Announces United States Department of Commerce Appointment of Brendan O'Grady to Investment Advisory Council

    Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that the U.S. Department of Commerce has selected Brendan O'Grady, Executive Vice President and Head of North America Commercial to serve on the U.S.

  20. Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society

    Late breaking data examines 10-year cost effectiveness of fremanezumab, while one oral presentation and 29 posters highlight FOCUS Phase IIIb study data in adult patients with migraine and documented inadequate response